305 related articles for article (PubMed ID: 34381020)
1. Fusion genes in gynecologic tumors: the occurrence, molecular mechanism and prospect for therapy.
Lu B; Jiang R; Xie B; Wu W; Zhao Y
Cell Death Dis; 2021 Aug; 12(8):783. PubMed ID: 34381020
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel ALK rearrangements in gynecologic clear cell carcinoma.
Yang C; Zhang L; Love-Gregory L; Sun L; Hagemann IS; Cao D
Int J Cancer; 2021 Jan; 148(2):459-468. PubMed ID: 33034056
[TBL] [Abstract][Full Text] [Related]
3. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Liu J; Westin SN
Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
[TBL] [Abstract][Full Text] [Related]
4. Genomic insights in gynecologic cancer.
Roddy E; Chapman J
Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
[TBL] [Abstract][Full Text] [Related]
5. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
6. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
7. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
Marks EI; Brown VS; Dizon DS
Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of gynecologic cancer.
Whang JD; Lee JH
J Korean Med Sci; 1997 Oct; 12(5):383-9. PubMed ID: 9364294
[TBL] [Abstract][Full Text] [Related]
9. Major clinical research advances in gynecologic cancer in 2015.
Suh DH; Kim M; Kim HJ; Lee KH; Kim JW
J Gynecol Oncol; 2016 Nov; 27(6):e53. PubMed ID: 27775259
[TBL] [Abstract][Full Text] [Related]
10. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
[TBL] [Abstract][Full Text] [Related]
11. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
12. Novel EPC1 gene fusions in endometrial stromal sarcoma.
Dickson BC; Lum A; Swanson D; Bernardini MQ; Colgan TJ; Shaw PA; Yip S; Lee CH
Genes Chromosomes Cancer; 2018 Nov; 57(11):598-603. PubMed ID: 30144186
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.
Wang Y; Hoang L; Ji JX; Huntsman DG
Annu Rev Pathol; 2020 Jan; 15():467-492. PubMed ID: 31977292
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma.
Dewaele B; Przybyl J; Quattrone A; Finalet Ferreiro J; Vanspauwen V; Geerdens E; Gianfelici V; Kalender Z; Wozniak A; Moerman P; Sciot R; Croce S; Amant F; Vandenberghe P; Cools J; Debiec-Rychter M
Int J Cancer; 2014 Mar; 134(5):1112-22. PubMed ID: 23959973
[TBL] [Abstract][Full Text] [Related]
15. Genomic-Based Therapy of Gynecologic Malignancies.
Markman M
Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
[TBL] [Abstract][Full Text] [Related]
16. T-cell target antigens across major gynecologic cancers.
Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
Sa JK; Hwang JR; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim J; Kim MS; Paik ES; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee Y; Her NG; Shin YJ; Cho HJ; Kim JY; Seo YJ; Koo H; Oh JW; Lee T; Kim HS; Song SY; Bae JS; Park WY; Han HD; Ahn HJ; Sood AK; Rabadan R; Lee JK; Nam DH; Lee JW
Genome Biol; 2019 Nov; 20(1):253. PubMed ID: 31771620
[TBL] [Abstract][Full Text] [Related]
18. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis and prognosis in gynecologic oncology.
Silverberg SG
Arch Pathol Lab Med; 1999 Nov; 123(11):1035-40. PubMed ID: 10539903
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
